Listed

NEUROONE MEDICAL TECHNOLOGIES Corp: Form 10-Q for the period ended Dec 31, 2021

Filed with the SEC on Feb 14, 2022 and accepted by EDGAR at Feb 14, 2022, 21:02 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2021-12-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2021-10-01 to 2021-12-31$33.7kus-gaap:Revenues
Cost of revenue3 months2021-10-01 to 2021-12-31$46.8kus-gaap:CostOfRevenue
Gross profit3 months2021-10-01 to 2021-12-31−$13.1kus-gaap:GrossProfit
Research and development3 months2021-10-01 to 2021-12-31$1.1mus-gaap:ResearchAndDevelopmentExpense
Operating income3 months2021-10-01 to 2021-12-31−$2.8mus-gaap:OperatingIncomeLoss
Net income3 months2021-10-01 to 2021-12-31−$2.8mus-gaap:NetIncomeLoss
Operating cash flow3 months2021-10-01 to 2021-12-31−$2.7mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure3 months2021-10-01 to 2021-12-31$61.5kus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2021-12-31$16.2mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2021-12-31$16.6mus-gaap:AssetsCurrent
Total assetsAt period end2021-12-31$17.2mus-gaap:Assets
Current liabilitiesAt period end2021-12-31$1.1mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2021-12-31$1.2mus-gaap:Liabilities
Shareholders' equityAt period end2021-12-31$15.9mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001213900-22-007486. Last ingested by Listed: Oct 24, 2026, 15:07 ET. Listed shows no prices and gives no investment advice.